The effects of the intraperitoneal administration of midazolam on blood glucose level and serum lipids in streptozotocin-induced diabetes in rats.
In male Wistar rats rendered diabetic by streptozotocin administration, the intraperitoneal (i.p.) injection of midazolam (2.5-5.0 and 10 mg/kg) induced a significant reduction of hyperglycemia and hyperlipidemia. The plasma immunoreactive insulin level was slightly, but significantly increased. The lethality was diminished.
Cuparencu
B
B
Department of Pharmacology, Faculty of Medicine, University of Oradea, Romania.
Horák
J
J
Orbai
P
P
Horák
A
A
Lenghel
A
A
D000818:Animals; D014151:Anti-Anxiety Agents / Q000008:administration & dosage; D001786:Blood Glucose / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D007274:Injections, Intraperitoneal; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood*; D008297:Male; D008874:Midazolam / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar
D014151:Anti-Anxiety Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007328:Insulin; D008055:Lipids; D008874:Midazolam